Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma by Takanori Abe et al.
RESEARCH Open Access
Dosimetric comparison of carbon ion
radiotherapy and stereotactic body
radiotherapy with photon beams for the
treatment of hepatocellular carcinoma
Takanori Abe1*, Jun-ichi Saitoh1, Daijiro Kobayashi1, Kei Shibuya1, Yoshinori Koyama1, Hirohumi Shimada2,
Katsuyuki Shirai2, Tatsuya Ohno2 and Takashi Nakano1
Abstract
Background: The purpose of this study was to compare carbon ion radiotherapy (C-ion RT) and stereotactic
radiotherapy (SBRT) with photon beams for the treatment of hepatocellular carcinoma (HCC), specifically with
regard to the dose volume parameters for target coverage and normal tissue sparing.
Methods: Data of 10 patients who were treated using C-ion RT with a total dose of 60 Gy(RBE) in four fractions were
used. The virtual plan of SBRT was simulated on the treatment planning computed tomography images of C-ion RT.
Dose volume parameters such as minimum dose covering 90 % of the planning target volume (PTV D90), homogeneity
index (HI), conformity index (CI), mean liver dose (MLD), volume of the liver receiving 5 to 60 Gy (V5-60), and max point
dose (Dmax) of gastrointestinal (GI) tract were calculated from both treatment plans.
Results: The PTV D90 was 59.6 ± 0.2 Gy(RBE) in C-ion RT, as compared to 56.6 ± 0.3 Gy in SBRT (p < 0.05). HI and CI were
1.19 ± 0.03 and 0.79 ± 0.06, respectively in C-ion RT, as compared to 1.21 ± 0.01 and 0.37 ± 0.02, respectively in
SBRT. Only CI showed a significant difference between two modalities. Mean liver dose was 8.1 ± 1.4 Gy(RBE) in
C-ion RT, as compared to 16.1 ± 2.5 Gy in SBRT (p < 0.05). V5 to V50 of liver were higher in SBRT than C-ion RT
and significant differences were observed for V5, V10 and V20. Dmax of the GI tract was higher in SBRT than C-ion RT,
but did not show a significantly difference.
Conclusions: C-ion RT provides an advantage in both target conformity and normal liver sparing compared with SBRT.
Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and third major cause of cancer-related
death worldwide [1]. Major causes of HCC are hepatitis
virus C, hepatitis virus B and alcohol abuse [2, 3], which
may result in hepatic dysfunction in HCC patients at
presentation. Surgical resection and percutaneous radio-
frequency ablation provide comparable local control rate
and overall survival [1, 4]. However, treatment efficacy
of both modalities deteriorates in patients with preexist-
ing hepatic dysfunction [5, 6]. For such patients,
radiation therapy using photon beams is applied. How-
ever, when conventional techniques are used, radiation
therapy is limited in its efficacy, due to the difficulty of
irradiating the local site while sparing normal liver,
which may cause radiation-induced liver disease (RILD)
[7]. Stereotactic body radiotherapy (SBRT) with photon
beams has been developed with highly precise and con-
formal beam delivery, which may decrease the dose to
the normal liver and provide a less invasive treatment
option for patients with hepatic dysfunction [8]. How-
ever, it is reported that even with SBRT, treatment effi-
cacy decreases substantially with increasing tumor size
[9, 10]. Particle beam radiotherapy such as proton and
carbon ion radiotherapy (C-ion RT) was applied for
HCC due to their physical advantages that deposit
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maximum energy sharply, with a penetration range. The
advantage of particle beam RT enables the delivery of an
adequate dose to the tumor while minimizing the dose
to surrounding normal tissue [11]. Proton therapy and
C-ion RT for HCC were reported to be effective and well
tolerated for advanced tumors [12–14]. In addition, car-
bon ion beams have a higher relative biological effect
due to larger mean linear energy transfer [15]. However,
no previous reports have compared dose volume param-
eters for C-ion RT versus SBRT with regard to target
volume coverage and sparing of organ at risk. Therefore,
the purpose of this study was to compare the dose
volume parameters to the target and organ at risk using
C-ion RT and SBRT in patients with HCC.
Methods
Patients
Since 2012, HCC patients have been treated with C-ion
RT at our institution. With approval from the institutional
review board of Gunma University Hospital, data from 10
consecutive HCC patients were used for this study.
Carbon ion radiotherapy
Patients received 60.0 Gy(RBE) in four fractions of C-ion
RT. In this study, the dose of C-ion RT is expressed as
Gy(RBE), which was calculated by multiplying the car-
bon physical dose (Gy) by the RBE. The RBE for thera-
peutic carbon beams is assumed to be three at a
neutron-equivalent depth of therapeutic carbon beams,
which is very near the distal end of the spread-out Bragg
peak (SOPB) [15, 16]. Carbon ion beams were generated
by the heavy particle accelerator at GHMC. For HCC
treatment, passive scattering technique was applied.
Energies of the accelerated beams were 290 MeV/u,
380 MeV/u, and 400 MeV/u. Beam energy was decided
according to the depth of the tumor. The SOBP is cre-
ated by the ridge filter. Beam range is adjusted by a
range shifter and range compensator. C-ion RT plans
were calculated using the XiO-N (ELEKTA, Stockholm,
Kingdom of Sweden and Mitsubishi Electric, Tokyo,
Japan). The XiO-N is a XiO (ELEKTA)-based treatment
planning system consisting of external dose calculation
engine “k2 Dose” and a source data management tool
(Mitsubishi Electric, Tokyo, Japan). Immobilization
devices such as fixation cushions and thermoplastic
shells (3 mm thickness) were used to acquire treatment
planning computed tomography (CT) images. After
immobilization, respiratory-gated CT images were ac-
quired. For treatment planning, images of the expiratory
phase were used. The gross tumor volume (GTV) was
defined on treatment planning CT by referring to the
fused CT image with a contrast material at the arterial
phase. The clinical target volume (CTV) margin, includ-
ing subclinical disease invasion, was added to the GTV,
adding 5 mm in all directions (excluding the chest wall).
The internal margin (IM) was determined by the tumor
motion demonstrated in 4-D CT images to encompass
residual respiratory tumor motion. The planning target
volume (PTV) included the CTV, IM, and setup margin
(3 mm). The Gating window was set to 30 % of the
expiratory phase to 30 % of the inspiratory phase to
minimize the influence of tumor respiratory motion.
Planning are described in a previous study [17].
Treatment planning of stereotactic body radiotherapy
The treatment plan of 60 Gy in four fractions of SBRT
was simulated on the CT images of patients who re-
ceived C-ion RT. Planning aim was to cover the PTV for
at least 90 % of the prescribed dose. Treatment plan
were calculated by treatment planning system of the
photon therapy (Eclipse, Varian Medical Systems, Inc.
California, USA). All the contours were the same as
those of the C-ion RT. SBRT plans employed seven co-
planar 10 MV photon beams with an even distribution
of gantry angles with avoiding gastrointestinal (GI) tract
and spinal cord. The weights of each field were also
arranged to cover the PTV for at least 90 % of the pre-
scribed dose and minimize the dose to the OARs. All
treatment plans for C-ion RT were created by medical
physicists and delivered to patients. All SBRT plans were
created by single radiation oncologist for this study.
Dose volume parameters
The following dose volume parameters were assessed for
PTV; minimum dose covering 90 % of the planning
target volume (PTV D90), homogeneity index (HI;
maximum dose/minimum dose in the target), and con-
formity index (CI; volume receiving the prescribed dose/
target volume) [18]. To compare normal tissue sparing,
the following dose volume parameters were assessed for
normal liver and GI tract. Normal liver was defined as
liver except GTV. Mean liver dose (MLD), normal
liver volumes receiving more than 5 Gy(RBE) (V5),
20 Gy(RBE) (V20), 30 Gy(RBE) (V30), 40 Gy(RBE)
(V40), 50 Gy(RBE) (V50), and 60 Gy(RBE) (V60), and
maximum point dose (Dmax) to the GI tract were cal-
culated. Mean parameters in the two modalities were com-
pared by Student’s t-test and P < 0.05 was considered
statistically significant. All statistical analyses were per-
formed using IBM SPSS Statistics for Windows, Version
21.0 (SPSS Inc., Armonk, NY, USA).
Results
Patient characteristics
Ten patients were included in this study. Tumor sites were
as follows: S1 (1 patient), S4 (2 patients), S6 (1 patient), S7
(4 patients), and S8 (2 patients). T stages were as follows:
T1 (8 patients), T2 (1 patient), and T3 (2 patients). The
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mean diameter of the GTV was 4.8 cm (range; 1.4 –
8.0 cm) and mean values for the GTV and PTV were
40.3 cm3 (range; 0.69 – 151.1 cm3) and 110.8 cm3 (range;
12.4 – 321.2 cm3), respectively.
Dose volume parameters
Representative dose distributions of SBRT and C-ion RT
are shown in Figs. 1 and 2. Dosimetric parameters of
C-ion RT and SBRT were calculated from both treat-
ment plans and summarized in Table 1. The PTV
D90 was 59.6 ± 0.2 Gy(RBE) for C-ion RT, as com-
pared to 56.6 ± 0.3 Gy for SBRT, indicating a significant
difference (p < 0.05). The HI and CI were 1.19 ± 0.03 and
0.79 ± 0.06, respectively, for C-ion RT, as compared to
1.21 ± 0.01 and 0.37 ± 0.02, respectively, for SBRT; only
CI showed a significant difference. MLD for normal tis-
sue sparing was 8.1 ± 1.4 Gy(RBE) for C-ion RT, as
compared to 16.1 ± 2.5 Gy for SBRT (p < 0.05). The rela-
tionship between MLD and GTV diameter is shown in
Fig. 3. V5 to V50 were higher in SBRT than C-ion RT,
while significant differences were observed for V5, V10,
and V20. Dmax of the GI tract was higher in SBRT than
C-ion RT, but did not constitute a significant difference.
Discussion
In this study, PTV D90 and CI showed significant differ-
ences between C-ion RT and SBRT while HI showed
no significant difference. CI was significantly higher
in C-ion RT, which indicates the superiority of C-ion
RT for its ability to generate more conformal dose
distribution than SBRT. The physical characteristics
of the carbon ion beam, specifically, the distal fall-off
of the Bragg peak and less lateral scatter contributed
to the more conformal and homogeneous dose delivery
to the target than SBRT.
Many reports have analyzed the relationship between
dosimetric parameters and RILD [19–21]. Tse et al re-
ported that no RILD requiring treatment occurred in the
patient for whom the MLD was less than 22 Gy with a
total dose of 24 – 60 Gy in 6 fractions of hypofractio-
nated radiotherapy [20]. A MLD of 22 Gy in 6 fractions
is equal to 18.8 Gy(RBE) in four fractions, as calculated
by the linear quadratic equation model assuming an α/β
ratio of 3 for normal liver [22]. In our study, SBRT could
not achieve this dose constraint (MLD > 18.8 Gy) in four
of ten patients, while, C-ion RT could achieve the con-
straint in all patients, even though there were some
bulky tumors. In this study, the dose constraint could
not be satisfied for tumors with diameters of more than
approximately 4 cm with SBRT, which was shown in
(Fig. 3). This suggests that C-ion RT has advantage in
treating patients with bulky tumors. Pan et al. reported
that MLD should be less than 6 Gy in patients with poor
liver function case (Child-Pugh score B) [19]. In our
study, low dose volume for a normal liver (e.g., V5-20)






PTV D90 59.6 ± 0.2 (GyRBE) 56.6 ± 0.3 (Gy) p < 0.05
HI 1.19 ± 0.03 1.21 ± 0.01 p = 0.61
CI 0.79 ± 0.06 0.37 ± 0.02 p < 0.05
Mean liver dose 8.1 ± 1.4 (GyRBE) 16.1 ± 2.5 (Gy) p < 0.05
Liver V5 20.2 ± 3.2 % 53.8 ± 7.2 % p < 0.05
Liver V20 14.2 ± 2.5 % 31.5 ± 6.2 % p < 0.05
Liver V30 11.6 ± 2.3 % 19.7 ± 4.1 % p = 0.11
Liver V50 8.5 ± 1.8 % 9.7 ± 2.1 % p = 0.67
D max of GI tract 8.4 ± 4.3 (GyRBE) 17.4 ± 7.1 (Gy) p = 0.29
Abbreviations: PTV D90 Minimum dose covering the 90 % of planning target
volume, HI Homogeneity index, CI Conformity index, V5-50 Volume of liver
received more than 5 Gy to 50 Gy, GI tract Gastrointestinal tract
Fig. 1 Representative dose distribution of stereotactic body
radiotherapy. The thick light blue line shows the 30 Gy isodose line
Fig. 2 Representative dose distribution of carbon-ion radiotherapy.
Dose to the normal tissue is less than that in SBRT
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was significantly lower for C-ion RT than SBRT, and the
difference in DVH parameters between the two modal-
ities tended to be bigger in lower doses. Thus, C-ion RT
may have advantage for the patients with poor liver
function, due to its capacity to decrease low dose scat-
tering to the normal liver.
Dose volume parameters to the GI tract such as the
duodenum and stomach showed no significant differ-
ences between the two modalities in this study. With
our protocol of C-ion RT for the treatment of HCC with
four fractions, patients with tumor located less than
1 cm from the GI tract were not eligible due to the risk
of late complications such as ulceration and fistula.
Elimination of these patients may have let to the results
that no significant difference was observed in dose to
the GI tract between the two modalities. However,
D0.5 cm3 – D2cm3 and Dmax to GI tract tended to be
twice as high for SBRT than C-ion RT, although the dif-
ference was not significant. In our new protocol for
HCC locating adjacent GI tract, total dose and fraction-
ation were modified to 64.8 Gy(RBE) in 12 fractions
considering the tolerance dose to the GI tract. This new
protocol may allow for significantly more sparing of the
GI tract
The present study has some limitations which must be
noted. First, the RBE of carbon ion beams may be influ-
enced by fraction dose, clinical endpoint, and other fac-
tors, all of which may affect our results. In Japan where
a beam-scattering method with a passive beam delivery
system is used, the dose distributions of therapeutic
carbon ion beams are determined by in-vitro Human
Salivary Gland (HSG) cell survival response and by
clinical experience from fast neutron radiotherapy in
National Institute of Radiological Sciences (NIRS). Mod-
erate radiosensitivity of HSG cells is expected to be a
typical tumor response to carbon ion beams. Initially,
the biological dose distribution is designed in order to
cause a flat biological effect on HSG cells in the SOBP
region. Then, the entire biological dose distribution
is increased evenly to attain an RBE of 3.0 at a depth
where dose-averaged LET (linear energy transfer) is
80 keV/mum. At that point, biological experiments
have shown that carbon ions can be expected to have
a biological effect identical to that of fast neutrons,
which show a clinical RBE of 3.0 for fast neutron
radiotherapy at NIRS [16]. However, optimum dose-
fractionation schedules of C-ion RT, (60 Gy(RBE) in
four fractions) for HCC have been established through
clinical experience, including extensive dose escalation
studies at NIRS using the above RBE model [14]. On the
other hand, Kang et al and Jang et al reported favorable re-
sults with 60 Gy in three fractions of X-ray SBRT for HCC
[23, 24]. While the optimal dose to HCC in X-ray SBRT is
not established, 60 Gy in four fractions can be applied in
clinical settings. Therefore, we think that 60 Gy in four
fractions of X-ray SBRT could be candidate to compare
against of 60 Gy(RBE) in four fractions of C-ion RT for
this dosimetric comparative study. Second, this was a
mono-institutional study, and thus policy of the planner
could have produced some subjective bias. Treatment
plans for each modality were made by staff members of
varying experience levels who were blinded to each other.
Both of the planners were also blinded to the clinical
results of C-ion RT to reduce bias as much as possible.
Conclusions
In conclusion, C-ion RT for HCC provides an advantage
in both target conformity and normal liver sparing com-
pared with SBRT
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Fig. 3 Scatter plot diagram of the diameters of the gross tumor volume and mean liver dose. Stereotactic body radiotherapy could not achieve
the dose constraints for normal liver (mean liver dose > 18.8 Gy) in four patients for whom the tumor diameter was more than 4 cm
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